Literature DB >> 12419169

Cost of treating hypertension in the elderly.

René L Roberts1, Ralph E Small.   

Abstract

Hypertension is a common disease among the elderly, a population that will continue to grow over the next decade. Untreated hypertension can lead to cardiovascular events and mortality. Given the seriousness of this disease and the increase in the number of elderly with hypertension, this review focuses on the cost of treating hypertension in the elderly as described in recent publications. We found a limited number of articles related to the treatment of hypertension in the elderly. One publication provided insightful information pertaining to expenditures in the United States for hypertension in 1998. This article was the first to examine age distribution among persons 65 years and older. It has been shown that antihypertensive pharmacologic treatment significantly reduces the incidence of cardiovascular events. Without any other medical conditions, thiazide-like diuretics are recommended for the treatment of hypertension in the elderly due to their beneficial effects, low risk for side effects, and low cost. In general, it was found that the elderly have higher expenditures per capita for hypertension and per hypertensive condition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12419169     DOI: 10.1007/s11906-002-0020-7

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  10 in total

1.  Pharmacoeconomic principles and methods: an introduction for hospital pharmacists.

Authors:  L A Sanchez
Journal:  Hosp Pharm       Date:  1994-08

2.  Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis.

Authors:  B M Psaty; N L Smith; D S Siscovick; T D Koepsell; N S Weiss; S R Heckbert; R N Lemaitre; E H Wagner; C D Furberg
Journal:  JAMA       Date:  1997-03-05       Impact factor: 56.272

Review 3.  Overview of pharmacoeconomics and pharmaceutical outcomes evaluations.

Authors:  C E Reeder
Journal:  Am J Health Syst Pharm       Date:  1995-10-01       Impact factor: 2.637

4.  Medical care expenditures for hypertension, its complications, and its comorbidities.

Authors:  T A Hodgson; L Cai
Journal:  Med Care       Date:  2001-06       Impact factor: 2.983

Review 5.  Hypertension in the elderly.

Authors:  W C Cushman; H R Black
Journal:  Cardiol Clin       Date:  1999-02       Impact factor: 2.213

6.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1997-11-24

Review 7.  Economics of antihypertensive therapy in the elderly.

Authors:  E C Dunn; R E Small
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 8.  Treatment of hypertension in the elderly.

Authors:  Warren J Elliott; Henry R Black
Journal:  Am J Geriatr Cardiol       Date:  2002 Jan-Feb

Review 9.  Hypertension in the elderly.

Authors:  N M Kaplan
Journal:  Annu Rev Med       Date:  1995       Impact factor: 13.739

10.  Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials.

Authors:  M Moser; P R Hebert
Journal:  J Am Coll Cardiol       Date:  1996-04       Impact factor: 24.094

  10 in total
  1 in total

Review 1.  Pharmacoeconomics and aging.

Authors:  Silvia Bustacchini; Andrea Corsonello; Graziano Onder; Enrico Eugenio Guffanti; Flavio Marchegiani; Angela Marie Abbatecola; Fabrizia Lattanzio
Journal:  Drugs Aging       Date:  2009-12       Impact factor: 3.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.